194 related articles for article (PubMed ID: 20549348)
1. Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.
Hoenerhoff MJ; Shibata MA; Bode A; Green JE
Transgenic Res; 2011 Apr; 20(2):247-59. PubMed ID: 20549348
[TBL] [Abstract][Full Text] [Related]
2. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C
Oncogene; 2000 Feb; 19(8):1020-7. PubMed ID: 10713685
[TBL] [Abstract][Full Text] [Related]
3. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
Shibata MA; Maroulakou IG; Jorcyk CL; Gold LG; Ward JM; Green JE
Cancer Res; 1996 Jul; 56(13):2998-3003. PubMed ID: 8674054
[TBL] [Abstract][Full Text] [Related]
4. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
5. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
6. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene.
Maroulakou IG; Anver M; Garrett L; Green JE
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11236-40. PubMed ID: 7972041
[TBL] [Abstract][Full Text] [Related]
7. Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
Aprelikova O; Tomlinson CC; Hoenerhoff M; Hixon JA; Durum SK; Qiu TH; He S; Burkett S; Liu ZY; Swanson SM; Green JE
PLoS One; 2016; 11(5):e0155262. PubMed ID: 27171183
[TBL] [Abstract][Full Text] [Related]
8. STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.
Meyer-Losic F; Newman SP; Day JM; Reed MJ; Kasprzyk PG; Purohit A; Foster PA
PLoS One; 2013; 8(12):e80305. PubMed ID: 24324595
[TBL] [Abstract][Full Text] [Related]
9. The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer.
Shibata MA; Jorcyk CL; Liu ML; Yoshidome K; Gold LG; Green JE
Toxicol Pathol; 1998; 26(1):177-82. PubMed ID: 9502400
[No Abstract] [Full Text] [Related]
10. Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model.
Holzer RG; MacDougall C; Cortright G; Atwood K; Green JE; Jorcyk CL
Breast Cancer Res Treat; 2003 Jan; 77(1):65-76. PubMed ID: 12602905
[TBL] [Abstract][Full Text] [Related]
11. Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential.
Drobysheva D; Smith BA; McDowell M; Guillen KP; Ekiz HA; Welm BE
Breast Cancer Res; 2015 Oct; 17(1):132. PubMed ID: 26429062
[TBL] [Abstract][Full Text] [Related]
12. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
[TBL] [Abstract][Full Text] [Related]
13. Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.
Mao SPH; Park M; Cabrera RM; Christin JR; Karagiannis GS; Oktay MH; Zaiss DMW; Abrams SI; Guo W; Condeelis JS; Kenny PA; Segall JE
Breast Cancer Res; 2018 Oct; 20(1):131. PubMed ID: 30367629
[TBL] [Abstract][Full Text] [Related]
14. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors.
Tzeng YJ; Zimmermann C; Guhl E; Berg B; Avantaggiati ML; Graessmann A
Oncogene; 1998 Apr; 16(16):2103-14. PubMed ID: 9572491
[TBL] [Abstract][Full Text] [Related]
15. The SV40 small t-antigen prevents mammary gland differentiation and induces breast cancer formation in transgenic mice; truncated large T-antigen molecules harboring the intact p53 and pRb binding region do not have this effect.
Goetz F; Tzeng YJ; Guhl E; Merker J; Graessmann M; Graessmann A
Oncogene; 2001 Apr; 20(18):2325-32. PubMed ID: 11402328
[TBL] [Abstract][Full Text] [Related]
16. The uteroglobin promoter targets expression of the SV40 T antigen to a variety of secretory epithelial cells in transgenic mice.
Sandmöller A; Halter R; Gómez-La-Hoz E; Gröne HJ; Suske G; Paul D; Beato M
Oncogene; 1994 Oct; 9(10):2805-15. PubMed ID: 8084586
[TBL] [Abstract][Full Text] [Related]
17. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression.
Rao T; Ranger JJ; Smith HW; Lam SH; Chodosh L; Muller WJ
Breast Cancer Res; 2014 Jan; 16(1):R11. PubMed ID: 24457046
[TBL] [Abstract][Full Text] [Related]
18. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
Franks SE; Campbell CI; Barnett EF; Siwicky MD; Livingstone J; Cory S; Moorehead RA
Oncogene; 2012 Jul; 31(27):3298-309. PubMed ID: 22020329
[TBL] [Abstract][Full Text] [Related]
19. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage.
Zhu M; Yi M; Kim CH; Deng C; Li Y; Medina D; Stephens RM; Green JE
Genome Biol; 2011 Aug; 12(8):R77. PubMed ID: 21846369
[TBL] [Abstract][Full Text] [Related]
20. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
Deeb KK; Michalowska AM; Yoon CY; Krummey SM; Hoenerhoff MJ; Kavanaugh C; Li MC; Demayo FJ; Linnoila I; Deng CX; Lee EY; Medina D; Shih JH; Green JE
Cancer Res; 2007 Sep; 67(17):8065-80. PubMed ID: 17804718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
